Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Leung, Y-Y, Holland, R, Mathew, AJ, Lindsay, C, Goel, N, Ogdie, A, Orbai, A-M, Hojgaard, P, Chau, J, Coates, LC, Strand, V, Gladman, DD, Christensen, R, Tillett, W & Mease, P 2020, 'Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review' Seminars in Arthritis and Rheumatism, bind 50, nr. 5, s. 1158-1181. https://doi.org/10.1016/j.semarthrit.2020.05.022

APA

CBE

Leung Y-Y, Holland R, Mathew AJ, Lindsay C, Goel N, Ogdie A, Orbai A-M, Hojgaard P, Chau J, Coates LC, Strand V, Gladman DD, Christensen R, Tillett W, Mease P. 2020. Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review. Seminars in Arthritis and Rheumatism. 50(5):1158-1181. https://doi.org/10.1016/j.semarthrit.2020.05.022

MLA

Vancouver

Author

Leung, Ying-Ying ; Holland, Richard ; Mathew, Ashish J ; Lindsay, Christine ; Goel, Niti ; Ogdie, Alexis ; Orbai, Ana-Maria ; Hojgaard, Pil ; Chau, Jeffrey ; Coates, Laura C ; Strand, Vibeke ; Gladman, Dafna D ; Christensen, Robin ; Tillett, William ; Mease, Philip. / Clinical trial discrimination of physical function instruments for psoriatic arthritis : A systematic review. I: Seminars in Arthritis and Rheumatism. 2020 ; Bind 50, Nr. 5. s. 1158-1181.

Bibtex

@article{82a732f23c5d403aa98ba6e91aaed4a9,
title = "Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review",
abstract = "OBJECTIVES: Physical function (PF) is a core domain to be measured in randomized controlled trials (RCTs) of psoriatic arthritis (PsA), yet the discriminative performance of patient reported outcome measures (PROMs) for PF in RCTs has not been evaluated systematically. In this systematic review, we aimed to evaluate the clinical trial discrimination of PF-PROMs in PsA RCTs.METHODS: We searched PubMed and Scopus databases in English to identify all original RCTs on biological and targeted synthetic disease modifying anti-rheumatic drugs (DMARDs) conducted in PsA. We assessed quality in each article using the OMERACT good method checklist. Effect sizes (ES) for the PF-PROMs were calculated and appraised using a priori hypotheses. Evidence supporting clinical trial discrimination for each PF-PROM was summarized to derive recommendations.RESULTS: 35 articles from 31 RCTs were included. Four PF-PROMs had data for evaluation: HAQ-Disability Index (DI), HAQ-Spondyloarthritis (S), and Short Form 36-item Health Survey Physical Component Summary (SF-36 PCS) and Physical Functioning domain (SF-36 PF). As anticipated, higher ES values were observed for intervention groups than the control groups. Across all studies, for HAQ-DI, the median ES were -0.73 and -0.24 for intervention and control groups, respectively. Whereas for SF-36 PCS, the median ES were 0.77 and 0.23. For intervention and control groups, respectively.CONCLUSION: Clinical trial discrimination was supported for HAQ-DI and SF-36 PCS in PsA with low risk of bias; and for SF-36 PF and HAQ-S with some caution. More studies are required for HAQ-S.",
author = "Ying-Ying Leung and Richard Holland and Mathew, {Ashish J} and Christine Lindsay and Niti Goel and Alexis Ogdie and Ana-Maria Orbai and Pil Hojgaard and Jeffrey Chau and Coates, {Laura C} and Vibeke Strand and Gladman, {Dafna D} and Robin Christensen and William Tillett and Philip Mease",
note = "Copyright {\circledC} 2020 Elsevier Inc. All rights reserved.",
year = "2020",
month = "10",
doi = "10.1016/j.semarthrit.2020.05.022",
language = "English",
volume = "50",
pages = "1158--1181",
journal = "Seminars in Arthritis and Rheumatism",
issn = "0049-0172",
publisher = "W.B./Saunders Co",
number = "5",

}

RIS

TY - JOUR

T1 - Clinical trial discrimination of physical function instruments for psoriatic arthritis

T2 - A systematic review

AU - Leung, Ying-Ying

AU - Holland, Richard

AU - Mathew, Ashish J

AU - Lindsay, Christine

AU - Goel, Niti

AU - Ogdie, Alexis

AU - Orbai, Ana-Maria

AU - Hojgaard, Pil

AU - Chau, Jeffrey

AU - Coates, Laura C

AU - Strand, Vibeke

AU - Gladman, Dafna D

AU - Christensen, Robin

AU - Tillett, William

AU - Mease, Philip

N1 - Copyright © 2020 Elsevier Inc. All rights reserved.

PY - 2020/10

Y1 - 2020/10

N2 - OBJECTIVES: Physical function (PF) is a core domain to be measured in randomized controlled trials (RCTs) of psoriatic arthritis (PsA), yet the discriminative performance of patient reported outcome measures (PROMs) for PF in RCTs has not been evaluated systematically. In this systematic review, we aimed to evaluate the clinical trial discrimination of PF-PROMs in PsA RCTs.METHODS: We searched PubMed and Scopus databases in English to identify all original RCTs on biological and targeted synthetic disease modifying anti-rheumatic drugs (DMARDs) conducted in PsA. We assessed quality in each article using the OMERACT good method checklist. Effect sizes (ES) for the PF-PROMs were calculated and appraised using a priori hypotheses. Evidence supporting clinical trial discrimination for each PF-PROM was summarized to derive recommendations.RESULTS: 35 articles from 31 RCTs were included. Four PF-PROMs had data for evaluation: HAQ-Disability Index (DI), HAQ-Spondyloarthritis (S), and Short Form 36-item Health Survey Physical Component Summary (SF-36 PCS) and Physical Functioning domain (SF-36 PF). As anticipated, higher ES values were observed for intervention groups than the control groups. Across all studies, for HAQ-DI, the median ES were -0.73 and -0.24 for intervention and control groups, respectively. Whereas for SF-36 PCS, the median ES were 0.77 and 0.23. For intervention and control groups, respectively.CONCLUSION: Clinical trial discrimination was supported for HAQ-DI and SF-36 PCS in PsA with low risk of bias; and for SF-36 PF and HAQ-S with some caution. More studies are required for HAQ-S.

AB - OBJECTIVES: Physical function (PF) is a core domain to be measured in randomized controlled trials (RCTs) of psoriatic arthritis (PsA), yet the discriminative performance of patient reported outcome measures (PROMs) for PF in RCTs has not been evaluated systematically. In this systematic review, we aimed to evaluate the clinical trial discrimination of PF-PROMs in PsA RCTs.METHODS: We searched PubMed and Scopus databases in English to identify all original RCTs on biological and targeted synthetic disease modifying anti-rheumatic drugs (DMARDs) conducted in PsA. We assessed quality in each article using the OMERACT good method checklist. Effect sizes (ES) for the PF-PROMs were calculated and appraised using a priori hypotheses. Evidence supporting clinical trial discrimination for each PF-PROM was summarized to derive recommendations.RESULTS: 35 articles from 31 RCTs were included. Four PF-PROMs had data for evaluation: HAQ-Disability Index (DI), HAQ-Spondyloarthritis (S), and Short Form 36-item Health Survey Physical Component Summary (SF-36 PCS) and Physical Functioning domain (SF-36 PF). As anticipated, higher ES values were observed for intervention groups than the control groups. Across all studies, for HAQ-DI, the median ES were -0.73 and -0.24 for intervention and control groups, respectively. Whereas for SF-36 PCS, the median ES were 0.77 and 0.23. For intervention and control groups, respectively.CONCLUSION: Clinical trial discrimination was supported for HAQ-DI and SF-36 PCS in PsA with low risk of bias; and for SF-36 PF and HAQ-S with some caution. More studies are required for HAQ-S.

U2 - 10.1016/j.semarthrit.2020.05.022

DO - 10.1016/j.semarthrit.2020.05.022

M3 - Journal article

VL - 50

SP - 1158

EP - 1181

JO - Seminars in Arthritis and Rheumatism

JF - Seminars in Arthritis and Rheumatism

SN - 0049-0172

IS - 5

ER -

ID: 61193802